Adenoviral Gene Therapy
- 1 February 2002
- journal article
- review article
- Published by Oxford University Press (OUP) in The Oncologist
- Vol. 7 (1) , 46-59
- https://doi.org/10.1634/theoncologist.7-1-46
Abstract
Learning Objectives: After completing this course, the reader should be able to:Understand the advantages and disadvantages of recombinant adenoviral vectors for gene delivery.Review the current biological strategies employed in clinical trials utilizing adenoviral mediated gene therapy for cancer.Understand modifications that may improve the utility of adenoviral vectors for gene therapy approaches.Access CME test online and receive one hour category 1 credit at CME.TheOncologist.comAs of May 2001, 532 gene therapy protocols had been approved for evaluation in clinical trials; however, only five of those had been evaluated in phase III clinical trials. Among the most commonly used vectors for the delivery of genetic material into human cells are the adenoviruses. Remarkable progress has been made with these vectors in the last decade, but some shortcomings continue to challenge investigators. The newly acquired knowledge of the adenoviral life cycle and the positive outcomes from phase II clinical trials have led to the application of vectors engineered to selectively target tumor tissue under controlled promoters.Keywords
This publication has 109 references indexed in Scilit:
- Biology of E1-Deleted Adenovirus Vectors in Nonhuman Primate MuscleJournal of Virology, 2001
- Evaluation of the Biodistribution, Persistence, Toxicity, and Potential of Germ-Line Transmission of a Replication-Competent Human Adenovirus Following Intraprostatic Administration in the MouseMolecular Therapy, 2000
- Evaluation of an E1E4-Deleted Adenovirus Expressing the Herpes Simplex Thymidine Kinase Suicide Gene in Cancer Gene TherapyHuman Gene Therapy, 1999
- Genomic DNA transfer with a high-capacity adenovirus vector results in improved in vivo gene expression and decreased toxicityNature Genetics, 1998
- Adeno-associated Virus Vector Containing the Herpes Simplex Virus Thymidine Kinase Gene Causes Complete Regression of Intracerebrally Implanted Human Gliomas in Mice, in Conjunction with Ganciclovir AdministrationJapanese Journal of Cancer Research, 1998
- Gene Therapy for Cancer: What Have We Done and Where Are We Going?JNCI Journal of the National Cancer Institute, 1997
- The use of adenoviral vectors for gene therapy and gene transfer in vivoCurrent Opinion in Biotechnology, 1995
- Long–term hepatic adenovirus–mediated gene expression in mice following CTLA4Ig administrationNature Genetics, 1995
- Adenovirus-Mediated Gene Therapy in an Experimental Model of Breast Cancer Metastatic to the BrainHuman Gene Therapy, 1995
- Adenovirus-mediated gene therapy for experimental spinal cord tumors: tumoricidal efficacy and functional outcomeBrain Research, 1995